While the battle over health care reform is far from over, the bill was passed into law. This huge step cleared up much of the uncertainty surrounding those companies affected by any changes.

All politics aside, there are certain facts that are clear. More people will be insured, which means more spending on related products and services. Could you imagine how other industries would thrive if they knew their customer base was about to grow by millions?

But Which Stocks Will Benefit?

While I will be the first to admit that I do not know many of the specifics of the bill (actually I don't think anyone does), we do know certain sectors stand to gain.

Pharmaceutical companies in particular should see a glut of new customers. Many analysts have raised their expectations for both generic and brand-name drug makers.

3 Drug Makers Ready to Profit

I trimmed the field down to pharmaceutical companies with a Zacks Rank of #1 or #2 that have recently seen upward estimate revisions.

Mylan Inc (MYL) is one of the largest generic drug makers in the U.S. The company also has operations around the world that operate in both the generic and branded areas.

Over the past 2 months the full-year Zacks Consensus Estimate for 2010 is up 7 cents, to $1.60. Next year's projections are up 22 cents, to $1.96. Compare these levels to a profit of $1.30 cents last year and you have growth rates of 23% and 22%, respectively.

Thanks to the increasing projections, this Zacks #1 Rank is trading at a solid value as well. shares are exchanging hands at 14 times 2010 estimates and with a PEG ratio of 0.9 times.

Questcor Pharmaceuticals (QCOR) has several branded drugs for the treatment of some central nervous system and sleep disorders.

In the past month full-year estimates have spiked. The Zacks Consensus Estimate for 2010 is now 59 cents, which almost doubled in the past month. Next year's forecasts are averaging 73 cents, 40 cents higher than 1 month ago.

Growth rates for this Zacks Rank #1 are now 47% for 2010 and another 25% in 2011. Thanks to the rising estimates shares are trading at 14 times forward earnings and with a PEG ratio of only 0.6 times.

Warner Chilcott plc (WCRX) makes pharmaceuticals for gastroenterology, women's healthcare, dermatology and urology. The company distributes is products Western Europe and North America.

Over the past 2 months, the full-year Zacks Consensus Estimate is up 13 cents to $3.40. This represents a growth rate of nearly 80%. Analysts are expecting the Zacks #1 Rank stock to earn $3.79 in 2011, which is up 29 cents over the same period of time.

In addition to the surging estimates, shares of WCRX are trading at great valuations. The forward P/E is coming in at just 7.5 times. Growth is also coming at a bargain, as the PEG ratio is just 0.6 times.

Additional Resources

Research Wizard trial offer

Zacks Equity Research

Bill Wilton is the Growth Stock Strategist for Zacks.com. He is also the Editor in charge of the market-beating Zacks Growth Trader service